Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
2019 ◽
Vol 6
(2)
◽
pp. 217-230
◽
2011 ◽
Vol 15
(2)
◽
pp. 264-275
◽
Keyword(s):
Keyword(s):
2018 ◽
Vol 113
◽
pp. S16
2013 ◽
Vol 108
(12)
◽
pp. 1824-1830
◽